Sensipar (Cinacalcet Hydrochloride) - Summary

SENSIPAR SUMMARY

Sensipar™ (cinacalcet hydrochloride) is a calcimimetic agent that increases the sensitivity of the calcium-sensing receptor to activation by extracellular calcium.

Sensipar™ is indicated for the treatment of secondary hyperparathyroidism in patients with Chronic Kidney Disease on dialysis.

Sensipar™ is indicated for the treatment of hypercalcemia in patients with parathyroid carcinoma.

SENSIPAR NEWS HIGHLIGHTS

Published Studies Related to Sensipar (Cinacalcet)

Cinacalcet for secondary hyperparathyroidism in children with end-stage renal disease. [2008.05.27]

An assessment of cinacalcet HCl effects on bone histology in dialysis patients with secondary hyperparathyroidism. [2008.04]

Dose determination of cinacalcet hydrochloride in Japanese hemodialysis patients with secondary hyperparathyroidism. [2008.04]

The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. [2008.01]

Effect of cinacalcet hydrochloride, a new calcimimetic agent, on the pharmacokinetics of dextromethorphan: in vitro and clinical studies. [2007.10]

more>>

Clinical Trials Related to Sensipar (Cinacalcet)

Safety and Efficacy Study of AMG 073 in Hemodialysis Subjects [Completed]

SENSOR: Study to Investigate Cinacalcet Treatment in Haemodialysis Patients With Secondary Hyperparathyroidism [Completed]

START: Sensipar Treatment Algorithm to Reach K/DOQI Targets in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism [Completed]

Cinacalcet HCl in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism Not Receiving Dialysis [Completed]

Treatment for Patients With Secondary Hyperparathyroidism of End-Stage Renal Disease (ESRD) [Completed]

more>>